Remove Engineering Remove Marketing Remove RNA
article thumbnail

New tRNA tech aims to rewrite rare disease treatment

Drug Target Review

One company leading the charge in this revolution is Alltrna , whose pioneering work in engineered transfer RNA (tRNA) therapeutics is offering new hope for patients with rare genetic diseases. we are first focused on engineering tRNAs to restore protein production in diseases caused by premature termination codons.

article thumbnail

Building Korro Bio: A CEO’s Perspective on Innovation and Risk Management

LifeSciVC

Founding Vision: Harnessing RNA Editing for Transformative Medicine Korro Bio’s story began in 2018, co-founded by a remarkable group: Jean-François Formela, M.D. Academic specializing in RNA editing). The ability of modifying RNA enabled us to sidestep many of the potential risks associated with permanent DNA editing.

RNA
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Magic of Fast Feedback Loops

Codon

In the four years I’ve been working as a machine learning engineer at Dyno Therapeutics , a biotechnology company in Boston, I’ve become increasingly convinced that biologists have an almost masochistic tolerance for difficult and protracted work. Many CROs operate in small, captive markets with high switching costs.

article thumbnail

Levers for Biological Progress

Codon

Scientists are already building a model that can, for example, look at which RNA molecules are expressed in a cell at t=0 and predict how those molecules will change at t=1. SeqFISH, developed by Long Cai’s group at Caltech, maps the spatial positions of thousands of RNA, DNA, or protein molecules within single cells.

DNA
article thumbnail

BioDAOs are Community-Owned Research Translation Engines, Not Investment DAOs

Molecule Blog

Moving research from concept to market is like conducting a symphony — there are numerous players and stakeholders, each bringing their unique expertise to work in harmony and advance a project. If approved, the company can then market and distribute the therapeutic. How do BioDAOs differ from investment DAOs?

article thumbnail

Biopharma Money on the Move: December 2 – 8

The Pharma Data

The fully integrated pharmaceutical company creates value through China’s specialty pharmaceutical markets with focus on iron deficiency, pain management and respiratory. The engineered cells are protected by Sigilon’s Afibromer biomaterials matrix, which shields them from immune rejection and fibrosis. SciNeuro Pharmaceuticals .

RNA
article thumbnail

Women in STEM with Juliet Williams

Drug Target Review

This laid the groundwork for my career in drug discovery using novel modalities like small molecule inhibitors, antibodies, RNA interference (RNAi) and, currently, small molecule protein degraders – which are opportunities to change how we think about medicines. I’ve already had a number of ‘rocking chair’ moments in my career.